<DOC>
	<DOCNO>NCT02976467</DOCNO>
	<brief_summary>The purpose trial analysis safety efficacy chymase inhibitor BAY1142524 dose 25 mg BID comparison placebo use 6 month treatment period patient left-ventricular ( LV ) dysfunction myocardial infarction ( MI ) . BAY1142524 placebo give top evidence-based standard care left-ventricular dysfunction myocardial infarction . Primary objective analysis first sign efficacy determine favourable change functional parameter adverse cardiac remodelling ( i.e . endsystolic enddiastolic volume index , ejection fraction ) . Secondary objective analysis safety tolerability evidence incidence severity adverse event . 30 patient complete treatment verum 30 patient complete treatment placebo .</brief_summary>
	<brief_title>A Double-blind Study Investigate Efficacy , Safety Tolerability BAY 1142524 Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Patients first ST elevation myocardial infarction ( STEMI ) treat primary percutaneous intervention ( PCI ) thrombolysis within 24 hour symptom onset Diagnosis STEMI require presence follow three criterion : Typical clinical symptom chest pain , shortness breath 20 minute related myocardial infarction New ST elevation indicate myocardial infarction Significant elevation troponin T I least one value 99th percentile upper reference limit ( URL ) and/or elevation creatine kinase ( CK ) creatine kinase MB ( 610 % total CK ) At screen period , day 5 9 MI , patient LVEF â‰¤ 45 % infarct size &gt; 10 % LV mass ( measure LGEMRI , centralblinded evaluation ) . Contraindication perform contrastenhanced cardiac MRI LVEF &lt; 20 % History heart failure LVEF &lt; 50 % occurrence first STEMI Infarct size &gt; 45 % ( g/g ; LV mass ) 5 9 day myocardial infarction NYHA ( New York Heart Association ) class IV randomization Any plan cardiac intervention baseline MRI plan operation Nonischemic cause cardiomyopathy Diagnosis atrial fibrillation Systolic blood pressure &lt; 100 mm Hg &gt; 180 mm Hg ; diastolic blood pressure &lt; 50 mm Hg &gt; 110 mm Hg , heart rate &lt; 50 &gt; 100 beat/minute ; mean triplicate value randomization Clinically relevant hepatic dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>